Kapadi
↗Raleigh, North Carolina, USA
Kapadi is a premier global oncology-focused Clinical Research Organization (CRO) that provides end-to-end clinical development services. Formed in 2024 through the merger of Clinscience, OncoBay Clinical, and Exom Group, the company specializes in navigating the complexities of oncology, hematology, and cell and gene therapy (CGT) trials.
As part of the Humaneva Group, Kapadi leverages a vertically integrated model that includes a Site Management Organization (SMO) and advanced data analytics technology. They offer custom-curated solutions from concept to commercialization, supported by an extensive network of over 45 specialized cell and gene therapy sites across North America and Europe.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Private Equity
Total Raised:$50M
Investors:Viking Global Investors, NEUCA Group
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service Provider)
Modalities:Cell therapy, Gene therapy, mAb, Small molecule, CAR-T, NK Cell
Active Trials:100
Trial Phases:Phase 1: 40 | Phase 2: 40 | Phase 3: 20
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Humaneva Inc. (NEUCA Group)
Subsidiaries:Kapadi Spain SL, Exom Group, OncoBay Clinical
Key Partnerships:Moffitt Cancer Center (Scientific and manufacturing collaboration), Diligent Pharma (Qualification partnership), Leukemia & Lymphoma Society (Beat AML Master Clinical Trial)
COMPETITION
Position:Emerging
Competitors:Medpace, Novotech, TD2 (Translational Drug Development), Scimega, PPD (Thermo Fisher)
LEADERSHIP
Key Executives:
Krystyna Kowalczyk - CEO
Dannelle Palmer - COO
Marie Engels - CFO
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kapadi. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.